Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of financial assets measured at fair value on a recurring basis

The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of March 31, 2023
	Level 1		Level 2		Level 3		Total
Money market funds	$	17,174	$	—	$	—	$	17,174
Government-sponsored enterprise securities		—		25,442		—		25,442
Corporate bonds and commercial paper		—		12,926		—		12,926
Total	$	17,174	$	38,368	$	—	$	55,542


	Assets at Fair Value as of December 31, 2022
	Level 1		Level 2		Level 3		Total
Money market funds	$	4,155	$	—	$	—	$	4,155
US treasury bills		—		5,225		—		5,225
Government-sponsored enterprise securities		—		15,796		—		15,796
Corporate bonds and commercial paper		—		26,766		—		26,766
Total	$	4,155	$	47,787	$	—	$	51,942